Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that ...

Shares of Gilead Sciences (NASDAQ:GILD) dropped 2.8% Monday morning after reports emerged that U.S. Health and Human Services ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

In May 2024 Gilead shared stages with international gospel artistes Todd Galberth and Phil Thompson at the Mindset Conference ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead (GILD) wins the backing of an EU panel for lenacapavir, its twice-yearly injectable for prevention of HIV in ...